Research Agenda

We are primarily engaged in research pertaining to the development of vaccines and antivirals by:

1. Understanding the molecular determinants of virulence and antigenicity of pathogenic viruses, namely enterovirus 71 (EV-A71) and dengue virus
2. Understanding the immune responses of viral pathogens to novel vaccines — synthetic peptide-based and live attenuated  
3. Designing anti-viral strategies, namely antivirals and antiviral peptides against EV-A71 and dengue
4. Exploring the future development of therapeutics based on microRNAs in viral and bacterial diseases
5. Advancing the development of DNA vaccines against antibiotic resistant bacteria